Tobramycin Sulfate Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Tobramycin Sulfate Injection (injection) from Hospira, Inc., A Pfizer Company with status To Be Discontinued. The shortage was first posted on Jul 17, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Hospira, Inc., A Pfizer Company
- Package NDC
- 0409-3578-01
- Dosage Form
- Injection
- Presentation
- Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)
- Initial Posting
- Jul 17, 2026